Remopharma SRL
7.0 FTERemopharma reported total assets of €3.66m at the end of the 2025 financial year (annual accounts filed with the NBB on 18 Aug 2026), with 7 full-time equivalents.
The score of Remopharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +32 % Total assets +13 % Headcount (avg FTE) +32 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Remopharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 18 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 28 Aug 2024
Remopharma's financial analysis
- Solvency60.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Remopharma
Remopharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0806.560.542
- VAT number
- BE0806560542
- Peppol
- Registered · 0208:0806560542 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 24 Sep 2008
- Registered office
- 9170 Sint-Gillis-Waas
- Size
- Micro · 7.0 FTE
- Latest accounts
- 2025 · filed on 18 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Remopharma (SRL) has been based in Sint-Gillis-Waas since 2008, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 241,142 € and equity of €2.21m; its revenue is not published. With 7.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 60.2%, above the median of its sector (44.2%).
Companies similar to Remopharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Foch Retail sale of pharmaceutical products Châtelet · balance sheet €3.63m
- DE Maeyer - DE Ryck Retail sale of pharmaceutical products Wommelgem · balance sheet €3.62m
- Tornaphar Retail sale of pharmaceutical products Tournai · balance sheet €3.74m
- Patrimanne Retail sale of pharmaceutical products Stekene · balance sheet €3.82m
- Dansaert Retail sale of pharmaceutical products Brussels · balance sheet €3.93m
- Jeco Farma Retail sale of pharmaceutical products Brakel · balance sheet €3.38m
- Apotheek PHARMANOVA Retail sale of pharmaceutical products Houthulst · balance sheet €3.37m
- Hainapharma Retail sale of pharmaceutical products Aiseau-Presles · balance sheet €4.03m
Frequently asked questions about Remopharma
What is the revenue of Remopharma?
Remopharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Remopharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0806560542 for Remopharma, if the company is VAT-registered. Its company number (CBE) is 0806.560.542.
Where is the registered office of Remopharma?
According to the CBE register, the registered office of Remopharma is in 9170 Sint-Gillis-Waas.
What is the equity of Remopharma?
At the close of the 2025 financial year, the equity of Remopharma amounts to 2,205,160 €, a solvency of 60.2% of total assets.
How many people work at Remopharma?
7.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Remopharma?
The register lists 1 active mandates at Remopharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Remopharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →